Back to GetFilings.com
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED: SEPTEMBER 30, 2002
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM: _______ TO _________
COMMISSION FILE NO.: 0-19974
ICU MEDICAL, INC.
(Exact name of Registrant as provided in charter)
------------------------------------------------
Delaware 33-0022692
-------- ----------
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
951 Calle Amanecer, San Clemente, California 92673
- -------------------------------------------- -----
(Address of Principal Executive Offices) (Zip Code)
(949) 366-2183
(Registrant's Telephone No. Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days:
Yes XXX No
--- ---
Indicate by check mark whether the registrant is an accelerated filer (as
defined in the Exchange Act).
Yes XXX No
--- ---
Indicate the number of shares outstanding in each of the issuer's classes of
common stock, as of the latest practicable date:
Class Outstanding at November 12, 2002
----- --------------------------------
Common 14,144,526
ICU MEDICAL, INC.
INDEX
PART I - FINANCIAL INFORMATION PAGE NUMBER
- ------------------------------ -----------
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
- -----------------------------------------
Condensed Consolidated Balance Sheets, September 30, 2002 and
December 31, 2001 3
Condensed Consolidated Statements of Income for the three months ended
September 30, 2002 and 2001 4
Condensed Consolidated Statements of Income for the nine months ended
September 30, 2002 and 2001 5
Condensed Consolidated Statements of Cash Flows for the nine months ended
September 30, 2002 and 2001 6
Notes to Condensed Consolidated Financial Statements 7
ITEM 2.
- -------
Management's Discussion and Analysis of Financial Condition and Results of
Operations 8
ITEM 3.
- -------
Quantitative and Qualitative Disclosures About Market Risk 19
ITEM 4.
- -------
Controls and Procedures 19
PART II - OTHER INFORMATION 19
- ---------------------------
SIGNATURES 21
2
ICU MEDICAL, INC.
Condensed Consolidated Balance Sheets
September 30, 2002 and December 31, 2001
(all dollar amounts in thousands except share data)
(unaudited)
ASSETS
9/30/02 12/31/01
---------- ----------
CURRENT ASSETS:
Cash and cash equivalents $ 5,269 $ 3,901
Liquid investments 84,950 69,126
---------- ----------
Cash and liquid investments 90,219 73,027
Accounts receivable, net of allowance for doubtful accounts of $658 and
$581 as of September 30, 2002 and December 31, 2001, respectively 15,079 13,062
Inventories 5,326 1,594
Prepaid expenses and other 843 605
Deferred income taxes - current portion 2,461 2,113
---------- ----------
Total current assets 113,928 90,401
---------- ----------
PROPERTY AND EQUIPMENT, at cost: 52,941 44,947
Less--Accumulated depreciation (23,060) (19,825)
---------- ----------
Property and equipment, net 29,881 25,122
DEFERRED INCOME TAXES 1,129 963
OTHER ASSETS 915 856
---------- ----------
$ 145,853 $ 117,342
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 2,898 $ 2,401
Accrued liabilities 6,677 8,264
---------- ----------
Total current liabilities 9,575 10,665
---------- ----------
STOCKHOLDERS' EQUITY:
Convertible preferred stock, $1.00 par value
Authorized -- 500,000 shares, issued and outstanding -- none -- --
Common stock, $0.10 par value-
Authorized -- 80,000,000 shares, issued -- 13,937,376 and 13,300,743
shares at September 30, 2002 and December 31, 2001, respectively 1,394 887
Additional paid-in capital 60,075 45,765
Treasury stock, at cost -- 174,688 shares at December 31, 2001 -- (987)
Retained earnings 74,809 61,102
---------- ----------
Total stockholders' equity 136,278 106,677
---------- ----------
$ 145,853 $ 117,342
========== ==========
The accompanying notes are an integral part of these
condensed consolidated financial statements.
3
ICU MEDICAL, INC.
Condensed Consolidated Statements of Income
For the Three Months Ended
September 30, 2002 and September 30, 2001
(all dollar amounts in thousands except share and per share data)
(unaudited)
For the Three Months Ended
------------------------------
9/30/02 9/30/01
------------ ------------
NET SALES $ 20,105 $ 16,214
COST OF GOODS SOLD 8,541 6,867
------------ ------------
Gross profit 11,564 9,347
------------ ------------
OPERATING EXPENSES:
Selling, general and administrative 4,743 4,287
Research and development 384 241
------------ ------------
Total operating expenses 5,127 4,528
------------ ------------
Income from operations 6,437 4,819
INVESTMENT INCOME 339 450
------------ ------------
Income before income taxes 6,776 5,269
PROVISION FOR INCOME TAXES 2,500 1,950
------------ ------------
NET INCOME $ 4,276 $ 3,319
============ ============
NET INCOME PER SHARE
Basic $ 0.31 $ 0.26
Diluted $ 0.28 $ 0.23
============ ============
WEIGHTED AVERAGE NUMBER OF SHARES
Basic 13,895,280 12,903,625
Diluted 15,375,757 14,531,707
============ ============
The accompanying notes are an integral part of these
condensed consolidated financial statements.
4
ICU MEDICAL, INC.
Condensed Consolidated Statements of Income
For the Nine Months Ended
September 30, 2002 and September 30, 2001
(all dollar amounts in thousands except share and per share data)
(unaudited)
For the Nine Months Ended
------------------------------
9/30/02 9/30/01
------------ ------------
NET SALES $ 63,678 $ 48,172
COST OF GOODS SOLD 26,429 20,215
------------ ------------
Gross profit 37,249 27,957
------------ ------------
OPERATING EXPENSES:
Selling, general and administrative 15,398 11,890
Research and development 1,033 872
------------ ------------
Total operating expenses 16,431 12,762
------------ ------------
Income from operations 20,818 15,195
INVESTMENT INCOME 1,079 1,626
------------ ------------
Income before income taxes 21,897 16,821
PROVISION FOR INCOME TAXES 8,100 6,205
------------ ------------
NET INCOME $ 13,797 $ 10,616
============ ============
NET INCOME PER SHARE
Basic $ 1.01 $ 0.83
Diluted $ 0.90 $ 0.74
============ ============
WEIGHTED AVERAGE NUMBER OF SHARES
Basic 13,710,168 12,764,133
Diluted 15,281,644 14,360,578
============ ============
The accompanying notes are an integral part of these
condensed consolidated financial statements.
5
ICU MEDICAL, INC.
Condensed Consolidated Statements of Cash Flows
For the Nine Months Ended
September 30, 2002 and September 30, 2001
(all dollar amounts in thousands)
(unaudited)
For the Nine Months Ended
-------------------------
9/30/02 9/30/01
--------- ---------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income $ 13,797 $ 10,616
Adjustments to reconcile net income to net cash
provided by operating activities --
Depreciation and amortization 3,748 3,475
Net change in current assets and liabilities, and other (7,711) 2,292
--------- ---------
9,834 16,383
Tax benefits from exercise of stock options 8,141 2,365
--------- ---------
Net cash provided by operating activities 17,975 18,748
--------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment (8,446) (4,011)
Net change in liquid investments (15,824) (16,530)
--------- ---------
Net cash used in investing activities (24,270) (20,541)
--------- ---------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options 7,663 2,109
--------- ---------
Net cash provided by financing activities 7,663 2,109
--------- ---------
NET INCREASE IN CASH AND CASH EQUIVALENTS 1,368 316
CASH AND CASH EQUIVALENTS, beginning of the period 3,901 1,945
--------- ---------
CASH AND CASH EQUIVALENTS, end of the period $ 5,269 $ 2,261
========= =========
The accompanying notes are an integral part of these
condensed consolidated financial statements.
6
ICU MEDICAL, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2002
(All dollar amounts in thousands)
(unaudited)
NOTE 1: The accompanying unaudited interim condensed consolidated financial
statements have been prepared in accordance with accounting principles generally
accepted in the United States of America and pursuant to the rules and
regulations of the Securities and Exchange Commission and reflect all
adjustments, which consist of only normal recurring adjustments, which are, in
the opinion of Management, necessary to a fair statement of the consolidated
results for the interim periods presented. Results for the interim period are
not necessarily indicative of results for the full year. Certain information and
footnote disclosures normally included in consolidated financial statements
prepared in accordance with generally accepted accounting principles have been
condensed or omitted pursuant to such rules and regulations. The consolidated
financial statements should be read in conjunction with the consolidated
financial statements and notes thereto included in our 2001 Annual Report to
Stockholders.
NOTE 2: Inventories consisted of the following:
9/30/02 12/31/01
------- --------
Raw material $2,686 $1,290
Work in process 411 179
Finished goods 2,229 125
------- -------
Total $5,326 $1,594
======= =======
NOTE 3: Property and equipment, at cost, consisted of the following:
9/30/02 12/31/01
------- --------
Land, building and building
improvements $13,584 $13,584
Machinery and equipment 18,502 15,663
Furniture and fixtures 3,445 3,568
Molds 8,589 8,566
Construction in process 8,821 3,566
-------- --------
Total $52,941 $44,947
======== ========
NOTE 4: Basic net income per share is computed by dividing net income by the
weighted average number of common shares outstanding. Diluted net income per
share is computed by dividing net income by the weighted average number of
common shares outstanding plus dilutive securities. Our dilutive securities are
outstanding common stock options (excluding stock options with an exercise price
in excess of market value), less the number of shares that could have been
purchased with the proceeds from the exercise of the options, using the treasury
stock method, and were 1,480,477 and 1,628,082 for the three months ended
September 30, 2002 and 2001, respectively and 1,571,476 and 1,596,445 for the
nine months ended September 30, 2002 and 2001, respectively. Options that are
antidilutive because their average exercise price exceeded the average market
price of our common stock for the period approximated 210,000 and 105,000 for
the three months ended September 30, 2002 and 2001, respectively, and
approximately 145,000 and 85,000 for the nine months ended September 30, 2002
and 2001, respectively. Stock options of subsidiaries did not have a dilutive
effect.
7
All share and per share data for periods prior to 2002 has been
restated for a three-for-two stock split effected March 15, 2002.
NOTE 5: The effective tax rate differs from that computed at the federal
statutory rate of 34% principally because of the effect of state income taxes
partially offset by the effect of tax-exempt investment income and state tax
credits.
NOTE 6: We had sales to two customers equal to ten percent or greater of net
sales, as follows:
Quarter ended September 30, Nine Months ended September 30,
---------------------------- -------------------------------
2002 2001 2002 2001
---- ---- ---- ----
Abbott Laboratories 61% 57% 64% 51%
B. Braun Medical Inc. 10% 20% 10% 21%
NOTE 7: We are from time to time involved in various legal proceedings, either
as a defendant or plaintiff, most of which are routine litigation in the normal
course of business. We believe that the resolution of the legal proceedings in
which we are involved will not have a material effect on our financial position
or results of operations.
NOTE 8: In a series of transactions from October 31 to November 13, 2002, we
acquired Bio-Plexus, Inc. for approximately $10 million cash and assumption of
$1.2 million of debt. We currently estimate transaction costs and integration
costs will aggregate approximately $1 million. Bio-Plexus is located in Vernon,
Connecticut. Its principal products are blood collection needles under the
PUNCTURE-GUARD(R) name, which are designed to eliminate exposure to sharp,
contaminated needles. Bio-Plexus's sales for its year ended December 31, 2001
were $6.4 million. Bio-Plexus will be included in our consolidated financial
statements commencing November 1, 2002.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
We develop, manufacture, sell and distribute disposable medical
connection products. Our principal products are proprietary safe medical
connection devices for use in intravenous ("I.V.") therapy applications. We also
produce custom I.V. systems that incorporate our proprietary products and
low-cost, generic I.V. systems.
CRITICAL ACCOUNTING POLICIES
- ----------------------------
Our significant accounting policies are summarized in Note 1 to the
Consolidated Financial Statements included in our 2001 Annual Report to
Shareholders. In preparing our financial statements, we make estimates and
assumptions that affect the expected amounts of assets and liabilities and
disclosure of contingent assets and liabilities. We apply our accounting
policies on a consistent basis. As circumstances change, they are considered in
our estimates and judgments, and future changes in circumstances could result in
changes in amounts at which assets and liabilities are recorded.
8
Investment securities are all marketable and considered "available for
sale". See "Quantitative and Qualitative Disclosures about Market Risk" below.
Under our current investment policies, there is no significant difference
between cost and fair value. If our investment policies were to change, and
there were differences between cost and fair value, that difference, net of tax
effect, would be reflected as a separate component of stockholders' equity.
We record sales and related costs upon shipment of products to medical
product manufacturers or distributors. Our customers do not have any right of
return or price protection with respect to unsold product, except that we will
accept return of defective product. Returns, which historically have not been
significant, are estimated and provided for at the time of sale. We provide
price adjustments in the form of rebates to independent distributors in certain
circumstances; they are not payable until the product is resold by the
distributor, but they are accrued based on historical experience at the time we
sell the product to the distributor. All sales are in U.S. dollars.
Accounts receivable are stated at net realizable value. An allowance is
provided for estimated collection losses. Loss exposure is principally with
international distributors for whom normal payment terms are long in comparison
to our other customers and, to a lesser extent, domestic distributors. Many of
these distributors are relatively small and we are vulnerable to adverse
developments in their businesses that can hinder our collection of amounts due.
If there are significant doubts as to the collectibility of receivables at the
time of shipment, we defer recognition of the sale in income until the
receivable is collected. If actual collection losses exceed expectations, we
could be required to accrue additional bad debt expense, which could have an
adverse effect on our operating results in the period in which the accrual
occurs.
Inventories are stated at the lower of cost or market. We need to carry
many components to accommodate our rapid product delivery, and if we misestimate
demand or if customer requirements change, we may have components in inventory
that we may not be able to use. Most finished products are made only after we
receive orders, but for those that are not, we need to estimate what may not be
saleable. We regularly review inventory for slow moving items and write off all
items we do not expect to use in manufacturing, or finished products we do not
expect to sell. If actual usage of components or sales of finished goods
inventory varies from our estimates, we would be required to write off
additional inventory, which could have an adverse effect on our operating
results in the period in which the write-off occurs.
Property and equipment is carried at cost and depreciated on the
straight-line method over their estimated useful lives. The estimates of useful
lives are significant judgments in accounting for property and equipment,
particularly for molds and automated assembly machines which are custom made for
us. We may retire them on an accelerated basis if we replace them with larger or
more technologically advanced tooling. The remaining useful lives of all
property and equipment are reviewed regularly and lives are adjusted or assets
written off based on current estimates of future use. As part of that review,
property and equipment is reviewed for other indicators of impairment, but to
date we have not encountered circumstances indicating the carrying amount of an
asset, or group of assets, may not be recoverable. An unexpected shortening of
useful lives of property and equipment which significantly increases
depreciation provisions, or other circumstances causing us to record an
impairment loss on such assets, could have an adverse effect on our operating
results in the period in which the related charges are recorded.
9
GENERAL
The following table sets forth the net sales by product as a percentage
of total net sales for the periods indicated:
====================================== ========== ========== ========= ========== ========== ========== ==========
YTD YTD
PRODUCT LINE 1999 2000 2001 Q3-01 Q3-02 Q3-01 Q3-02
- -------------------------------------- ---------- ---------- --------- ---------- ---------- ---------- ----------
CLAVE(R) 68% 71% 74% 79% 69% 75% 72%
- -------------------------------------- ---------- ---------- --------- ---------- ---------- ---------- ----------
Custom and Generic I.V. Systems 11% 12% 13% 11% 20% 13% 17%
- -------------------------------------- ---------- ---------- --------- ---------- ---------- ---------- ----------
CLC2000(R) 1% 4% 3% 2% 4% 3% 4%
- -------------------------------------- ---------- ---------- --------- ---------- ---------- ---------- ----------
Lopez Valve(R) 4% 3% 2% 3% 2% 3% 2%
- -------------------------------------- ---------- ---------- --------- ---------- ---------- ---------- ----------
RF100-RF150 ("Rhino") 6% 5% 3% 1% 2% 3% 2%
- -------------------------------------- ---------- ---------- --------- ---------- ---------- ---------- ----------
Protected Needle Products and Other 10% 5% 5% 4% 3% 3% 3%
- -------------------------------------- ---------- ---------- --------- ---------- ---------- ---------- ----------
Total 100% 100% 100% 100% 100% 100% 100%
====================================== ========== ========== ========= ========== ========== ========== ==========
We sell our products to independent distributors and through agreements
with Abbott Laboratories ("Abbott") and B.Braun Medical Inc. ("B.Braun"), (the
"Abbott Agreements" and the "B.Braun Agreements," respectively) and certain
other medical product manufacturers. Most independent distributors handle the
full line of our products. Abbott and B.Braun both purchase CLAVE products,
principally bulk, non-sterile connectors. Abbott also purchases the Rhino, a
low-priced connector specifically designed for Abbott, and the CLC2000, and
under an agreement signed February 27, 2001, custom I.V. sets. B.Braun also
purchases the McGaw Protected Needle and pays us revenue sharing payments on its
sales of its SafeLine products. We also sell certain other products to a number
of other medical product manufacturers.
The Abbott Agreements extend to December 2009 and have extension
provisions beyond 2009. The B.Braun Agreement for CLAVE terminates on December
31, 2002, as further described under "Quarter Ended September 30, 2002 Compared
tothe Quarter Ended September 30, 2001".
We believe that as the healthcare provider market continues to
consolidate, our success in marketing and distributing CLAVE products will
depend, in part, on our ability, either independently or through strategic
supply and distribution arrangements, to secure long-term CLAVE contracts with
major buying organizations. Further, our marketing and distribution strategy may
result in a significant share of our revenues being concentrated among a small
number of distributors and manufacturers. The loss of a strategic supply and
distribution agreement with a customer or the loss of a large contract by such a
customer could have a material adverse effect on our operating results.
We believe the success of the CLAVE has, and will continue to motivate
others to develop one piece needleless connectors that may incorporate many of
the same functional and physical characteristics as the CLAVE. We are aware of a
number of such products. In response to competitive pressure, we have been
reducing prices to protect and expand our market. The price reductions to date
have been more than offset by increased volume. We expect that the average price
of our CLAVE products will continue to decline. There is no assurance that our
current or future products will be able to successfully compete with products
developed by others.
10
The federal Needlestick Safety and Prevention Act, enacted in November
2000, modified standards promulgated by the Occupational Safety and Health
Administration to require employers to use safety I.V. systems where appropriate
to reduce risk of injury to employees from needlesticks. We believe the effect
of this law will be to accelerate sales of our needleless systems, although we
are unable to estimate the amount or timing of such sales.
We are taking steps to reduce our dependence on our current proprietary
products. We are seeking to substantially expand our custom I.V. systems
business with products sold to medical product manufacturers and independent
distributors and expand selectively into the production of generic I.V. sets. On
February 27, 2001, we signed an agreement with Abbott under which we manufacture
all new custom I.V. sets for sale by Abbott, and we jointly promote the products
under the name SetSource(TM). We expect a significant increase in sales of
custom I.V.systems under this agreement. We had also launched SetFinder as a
separate subsidiary and it has been contracting with and distributing
commodity-type standard I.V. sets directly to healthcare providers and to group
purchasing organizations and independent dealer networks. SetFinder operations
were merged into independent domestic distribution operations in the second
quarter of 2002 and will continue as part of those operations. Custom and
generic I.V. systems accounted for almost $11 million of net sales in the first
nine months of 2002 and net sales under the Abbott SetSource program exceeded
$3.5 million in the same period. SetFinder has achieved a modest amount of sales
under its initiative, and we expect future increases from contracts it has
concluded and expects to conclude. However, there is no assurance as to the
longer-term success of either of these initiatives.
We have an ongoing program to increase systems capabilities, improve
manufacturing efficiency, reduce labor costs, reduce time needed to produce an
order, and minimize investment in inventory. The original focus was on
production of custom I.V. systems, which is relatively labor intensive; it now
includes all automated manufacturing operations as well. Manual assembly is now
performed at the facility opened in December 1998 in Ensenada, Baja California,
Mexico. In 1999, we made significant investment in automated molding and
assembly equipment. In the third quarter of 2002, we have commenced use of
automated assembly equipment for the 1o2 Valve(R) and have commenced use of
automated assembly equipment for the CLC2000(TM) in the fourth quarter of 2002.
Throughout 2002, we are adding molding and automated assembly capacity for CLAVE
production and in the third quarter of 2002 commenced a significant expansion of
our manual assembly capacity in Mexico which we expect to complete in early
2003. All these steps have reduced and will continue to reduce unit production
costs. Ongoing steps also include automation of the production of new products
and other products for which volume is growing, and consideration of
establishment of production facilities outside North America. Because
significant innovation is required to achieve these goals, there is no assurance
that these steps will achieve the desired results.
We distribute our products through three distribution channels. Net
sales for each distribution channel were as follows:
==================================== ========== ========== ========= ========== ========== ========== ==========
CHANNEL 1999 2000 2001 Q3-01 Q3-02 YTD YTD
Q3-01 Q3-02
- ------------------------------------ ---------- ---------- --------- ---------- ---------- ---------- ----------
Medical product manufacturers 71% 74% 72% 78% 71% 72% 74%
- ------------------------------------ ---------- ---------- --------- ---------- ---------- ---------- ----------
Independent domestic distributors 25% 21% 20% 14% 21% 20% 19%
- ------------------------------------ ---------- ---------- --------- ---------- ---------- ---------- ----------
International 4% 5% 8% 8% 8% 8% 7%
- ------------------------------------ ---------- ---------- --------- ---------- ---------- ---------- ----------
Total 100% 100% 100% 100% 100% 100% 100%
==================================== ========== ========== ========= ========== ========== ========== ==========
QUARTER ENDED SEPTEMBER 30, 2002 COMPARED TO THE QUARTER ENDED SEPTEMBER 30,
- ----------------------------------------------------------------------------
2001
- ----
NET SALES increased $3,891,000, or approximately 24%, to $20,105,000 in
the third quarter of 2002, compared to $16,214,000 during the same period last
year. The increase was principally attributable to a 114% increase in sales of
custom and generic I.V. systems and an 8% increase in sales of CLAVE Products.
Net sales to Abbott in the third quarter of 2002 were $12,051,000, as
compared with net sales of $9,229,000 in the third quarter of 2001. (Abbott
sales discussed in this paragraph do not include export sales.) Net sales of
CLAVE Products to Abbott, excluding custom I.V. systems, increased to $9,619,000
in the third quarter of 2002 from $8,550,000 in the third quarter of 2001 due to
11
an increase in unit volume partially offset by lower average selling
prices. Sales to Abbott under the SetSource program approximated $1,580,000 in
the third quarter of 2002 as compared with approximately $1,250,000 in the
second quarter of 2002. We expect a substantial increase in CLAVE unit and
dollar sales volume with Abbott through the balance of 2002, as well as a
significant increase in SetSource unit and sales volume. Net sales of CLC2000
and Rhino increased substantially over those in the third quarter of 2001, when
sales of those product lines were relatively low because Abbott was balancing
its inventory position. We expect a moderate increase in sales of the CLC2000 to
Abbott in the fourth quarter of 2002 over levels of both the fourth quarter of
2001 and the third quarter of 2002. We expect sales of the Rhino to decline in
the future as the market shifts to one piece, needleless, swabbable technology.
While we expect significant future sales to Abbott, there is no assurance as to
the amount of such increases.
Net sales to B.Braun, including revenue sharing, amounted to $2,218,000
in the third quarter of 2002, as compared with $3,319,000 in the third quarter
of 2001. Net sales of CLAVE Products were $1,810,000, or about one-third less
than what they were in the third quarter of 2001. The decrease in the
third quarter was in line with expectations. B.Braun's orders for the
fourth quarter of 2002 are substantially greater than our sales to them were
in the third quarter of 2002. As described below, we do not expect to sell
CLAVE Products to B.Braun after the fourth quarter of 2002, and we believe
that the increase in fourth quarter orders is attributable to B.Braun
increasing inventories of CLAVE Products while it is still able to purchase
from us. Other net sales to B.Braun, which consist of the McGaw Protected
Needle and SafeLine revenue sharing, decreased about 40% from the thir
quarter of 2001, and we expect those sales to decrease in the future as
the market for safe connectors continues to shift to one piece, needleless,
swabbable technology. In 2001, we became involved as plaintiff in litigation
with B.Braun over contractual and patent matters. As of November 13, 2002,
we reached a settlement with B.Braun on the contract litigation. In the
settlement, we agreed with B.Braun to dismiss the litigation over contractual
matters with prejudice and terminate the B.Braun Agreement for its purchase
of CLAVE Products from us. We do not expect to sell CLAVE Products to
B.Braun after December 31, 2002. B.Braun has a product, called UltraSite(TM),
that is competitive with the CLAVE, and which we have alleged is being
marketed and sold in violation of ICU's patent. We filed a patent
infringement suit against B.Braun in August 2001 and are vigorously pursuing
the matter. See Part II, Item 1. Legal Proceedings. B.Braun also sells a
number of other I.V. connectors. While the termination of the B.Braun CLAVE
agreement could have an adverse effect on us, we believe many of B.Braun's
customers prefer the CLAVE to B.Braun's products, including the UltraSite,
and that many of them will continue to buy CLAVE Products through other
sources when they are no longer available from B.Braun.
Net sales to independent domestic distributors increased approximately
79% from $2,360,000 in the third quarter of 2001 to $4,214,000 in the third
quarter of 2002. This is attributed to a 71% increase in custom I.V. systems
sales and an 83% increase in net sales of CLAVE Products, both due principally
to increased unit volume. Net sales of protected needle products, the CLC2000
and the Lopez Valve also increased over the third quarter of 2001, principally
because of volume increases. We expect continuing growth in sales to independent
domestic distributors, principally from sales of custom I.V. systems, and new
products such as the CLC2000 and the 1o2 Valve. We also expect additional sales
growth from sales by independent domestic distributors to former B.Braun
accounts. However, there is no assurance that we will achieve increased net
sales to independent domestic distributors in the future. Further, the ability
of the independent distributors to sustain or increase their sales may be
impacted by competition from existing and new competitive products or
acquisition of market share by Abbott.
Total sales to foreign distributors were $1,527,000 in the third
quarter of 2002, as compared with $1,207,000 in the third quarter of 2001.
(Those amounts do not include distribution in Canada, but do include other
export sales to Abbott.) Approximately $400,000 of foreign distributor orders
12
for delivery in the third quarter of 2002 were received too late in the quarter
for us to complete production and shipment, and were shipped in October 2002. We
now have distribution arrangements in the principal countries in Western Europe,
the Pacific Rim and South America and in South Africa. Furthermore, we have been
increasing the number of our international business development managers. As a
result, we expect significant increases in sales to foreign customers in the
future, although there is no assurance that those expectations will be realized.
We expect a significant increase in international sales in the fourth quarter of
2002 from the levels achieved in the third quarter of 2002.
Total net sales of CLAVE Products (excluding custom CLAVE I.V. systems)
increased from $12,765,000 in the third quarter of 2001 to $13,820,000 in the
third quarter of 2002, or 8%, due to an increase in unit shipments to Abbott and
domestic and international distributors, partially offset by decreased unit
shipments to B.Braun. Average net selling prices were unchanged from the third
quarter of 2001. We expect continued significant growth in CLAVE unit and dollar
sales volume in the fourth quarter of 2002, notwithstanding any decline in sales
to B.Braun because of the large growth that we expect with Abbott and
international distribution. However, we give no assurance that the expectations
will be realized.
In October 2001, we commenced production of the "MicroCLAVE(R)." It is
smaller than the existing CLAVE but is functionally similar. We will initially
market it as an extension of the CLAVE product line for use where its smaller
size is advantageous, such as pediatric care. Sales are included in CLAVE
product sales.
Net sales of custom and generic I.V. systems increased approximately
114% in the third quarter over those in the third quarter of 2001. Slightly over
half of the increase was in the Abbott SetSource program. Unit volume accounted
for the majority of the increase, and the balance resulted from higher average
selling prices due to a higher proportion of larger, more expensive, sets.
In November 1998, we introduced the 1o2 Valve, the first one-way or
two-way drug delivery system. After overcoming initial delays in production, we
re-launched the product in January 2000. Substantially all sales of the 1o2
Valve, which were approximately $680,000 in the third quarter of 2002, are in
custom I.V. systems, and are included in sales reported in that category.
Slightly over half of the sales in the 1o2 Valve are under the Abbott SetSource
program.
Net sales of the CLC2000 almost tripled in the third quarter of 2002 as
compared with the third quarter of 2001. Abbott, which had purchased only a
small amount of CLC2000s in the third quarter of 2001 as it balanced its
inventory position, accounted for about 75% of the increase. We expect sales of
the CLC2000 to increase in 2002 and later years, but there is no assurance as to
the amount or timing of future CLC2000 sales.
Net sales of the Lopez Valve increased 45% in the third quarter of 2002
over the third quarter of 2001 because of a 58% increase in net sales of this
product to independent domestic distributors because of higher unit shipments.
We believe that the focus of the sales and marketing efforts of our personnel
and our distributors on other products has and may continue to dilute sales of
the Lopez Valve and may contribute to quarterly fluctuations in sales volume. We
now expect sales of the Lopez Valve in the fourth quarter of 2002 to be
approximately the same as they were in the fourth quarter of 2001.
Net sales of protected needle products decreased slightly in the third
quarter of 2002 compared to the same period last year. The decline is because of
the safe-connector market's continued shift to one piece, swabbable, needleless
technology. We expect to continuing decrease in protected needle sales.
Our sales can fluctuate on a quarter-to-quarter basis because of
fluctuations in orders from our medical product manufacturer customers that may
not reflect their current sales volumes and normal seasonal fluctuations due to
lower censuses in healthcare facilities in summer months.
13
GROSS MARGIN was 58% during the third quarter of 2002, the same as in
the third quarter of 2001. The results of our continuing extensive efforts to
improve manufacturing efficiency and the increased absorption of overhead by
higher production volumes offset the effect of lower average unit selling
prices. Our gross margins for custom and generic I.V. systems and certain other
manually assembled products has been lower than those we have historically
achieved on other products because their production is relatively labor
intensive. While margins on them have been improving, as they become a larger
proportion of our sales, the overall gross margin may decrease somewhat.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES ("SG&A"), excluding
research and development expenses, increased 11% to $4,743,000, and was
approximately 24% of sales in 2002 as compared with 26% of sales in 2001. The
dollar increase was evenly divided between administrative expenses and sales and
marketing expenses. Administrative expenses increased principally because of
legal fees related to the litigation with B.Braun. Sales and marketing expenses
increased because of increases in headcount and in promotional costs, but
overall sales and marketing expenses decreased as a percentage of sales in the
third quarter of 2002 from 14% to 12%. We expect continued growth in SG&A
expenses in 2002, but we expect them to grow at a lower rate than our growth in
net sales. However, there can be no assurance that these expectations will be
realized
RESEARCH AND DEVELOPMENT EXPENSES ("R&D") increased approximately 59%
in the third quarter of 2002 as compared with the third quarter of 2001.
Spending is principally on new product development, which increased over last
year, and software development to support manufacturing and distribution of
custom and generic I.V. systems. We estimate that R&D costs will continue in
2002 at approximately the same percentage of net sales as in 2001. However R&D
costs could differ from those estimates and the R&D projects may not be
completed as expected.
We plan to launch, in limited markets, a new I.V. connector currently
under development. We expect to apply in 2003 to the FDA under Section 510(k) of
the FDC Act for approval to market this new connector. There is no assurance
that the FDA will grant marketing clearance, that we will launch this new
product, or that it will achieve sales if and when we commence marketing it.
INCOME FROM OPERATIONS increased $1,618,000 or 34% and was 32% of net
sales in the third quarter of 2002, as compared with 30% in the third quarter of
2001. Gross profit increased $2,217,000 while operating expenses increased only
$599,000.
INVESTMENT INCOME declined in the third quarter of 2002 as compared
with the third quarter of 2001, notwithstanding the increase in the investment
portfolio, because of declines in interest rates since the beginning of 2001.
INCOME TAXES were accrued at an effective tax rate of 37% in the third
quarter of both 2002 and 2001. We expect our effective tax rate for the full
year 2002 to be approximately 37%.
NET INCOME increased 29% to $4,276,000 in the third quarter of 2002 as
compared with $3,319,000 in the comparable period last year. NET INCOME PER
SHARE - DILUTED increased 22% to $0.28 per share in the third quarter of 2002.
The percentage increase was less than that for net income because there were
more shares outstanding and there were more dilutive shares as a result of the
higher market price of our common stock.
NINE MONTHS ENDED SEPTEMBER 30, 2002 COMPARED TO THE NINE MONTHS ENDED SEPTEMBE
- -------------------------------------------------------------------------------
30, 2001
- --------
NET SALES increased $15,506,000, or approximately 32%, to $63,678,000
in the first nine months of 2002 compared to $48,172,000 during the same period
last year. The increase was primarily attributable to a 28% increase in sales of
CLAVE Products and a 68% increase in sales of custom and generic I.V. systems.
14
Net sales to Abbott in the first three quarters of 2002 were
$40,611,000, as compared with net sales of $24,682,000 in the first three
quarters of 2001. (Abbott sales discussed in this paragraph do not include
export sales.) Net sales of CLAVE Products to Abbott, excluding custom CLAVE
I.V. systems increased to $34,094,000 in the first three quarters of 2002 from
$21,678,000 in the first three quarters of 2001 due to a 72% increase in unit
volume partially offset by lower average selling prices. Sales to Abbott under
the SetSource program, which was new in 2001, approximated $3,683,000 in the
first three quarters of 2002 as compared with approximately $500,000 in the
first three quarters of 2001.
Net sales to B.Braun, including revenue sharing, amounted to $6,170,000
in the first three quarters of 2002, as compared with $9,945,000 in the first
three quarters of 2001. Net sales of CLAVE Products in the first three quarters
of 2002 decreased to $4,931,000, to about 60% of what they were in the first
three quarters of 2001. The decrease was principally because of a decrease in
unit sales of CLAVE Products, in part because we believe B.Braun's purchase of
CLAVE Products in the latter half of 2001 exceeded their sales to customers, and
in part for the reasons described above under "Quarter Ended September 30, 2002
Compared to the Quarter Ended September 30, 2001". The decrease in the first
three quarters was in line with expectations.
Net sales to independent domestic distributors, including sales through
SetFinder, increased approximately 24% from $9,585,000 in the first three
quarters of 2001 to $11,920,000 in the first three quarters of 2002. Over 80% of
this increase is attributed to an increase in net sales of custom and generic
I.V. systems with the balance spread across all other product lines. These
increases were principally from increased unit volume.
Total sales to foreign distributors were $4,598,000 in the first three
quarters of 2002, as compared with $3,802,000 in the first three quarters of
2001. (These amounts do not include distribution in Canada, but do include other
export sales to Abbott.) Unit volumes increased because of of our increased
distribution capabilities and success of our sales efforts.
Total sales of CLAVE Products (excluding custom CLAVE I.V. systems)
increased from $35,939,000 in the first three quarters of 2001 to $45,961,000 in
the first three quarters of 2002, or 28%. Increased unit shipments to Abbott and
domestic and international distributors were partially offset by decreased unit
shipments to B.Braun and a decrease in average net selling prices of
approximately 6%.
Net sales of custom and generic I.V. systems increased approximately
68% in the first three quarters of 2002 over those in the first three quarters
of 2001. Approximately three-quarters of the increase was in the Abbott
SetSource program. Unit volume accounted for virtually all of the increase.
Net sales of custom I.V. sets containing a 1o2 Valve were $1,850,000
for the first nine months of 2002, and slightly over half of those sales were
under the Abbott SetSource program.
Net sales of the CLC2000 increased from $1,170,000 in the first three
quarters of 2001 to $2,456,000 in the first three quarters of 2002. Abbott
accounted for approximately 65% of the increase, with most of the balance from
independent domestic distributors.
Net sales of the Lopez Valve increased 8% in the first three quarters
of 2002, principally because of an increase in sales of this product to
independent domestic distributors and a small amount of shipments to medical
products manufacturers.
Net sales of protected needle products decreased 20% in the first three
quarters of 2002 compared to the same period last year. The decline is because
of the safe-connector market's continued shift to one piece, swabbable,
needleless technology.
15
GROSS MARGIN was 58% for the first nine months of 2002 as compared to
58% during the first nine months of 2001. Although average selling prices have
continued to decrease over the first six months of 2002, this was offset by a
decrease in unit manufacturing costs.
SG&A excluding research and development expenses, increased by
$3,508,000 to $15,398,000, and were 24% of net sales, down from 25% for the
first three quarters of 2001. The spending increase was principally for
administrative expenses, including litigation costs; administrative expenses
increased approximately $1,984,000 and were 11% of sales in the first three
quarters of 2002 as compared with 10% in the first three quarters of 2001. Sales
and marketing costs increased approximately $1,524,000 because of increases in
headcount and in promotional costs, but decreased as a percentage of sales from
15% to 14%.
R&D increased for the first three quarters of 2002 by approximately 18%
principally because of spending on a new product development.
INCOME FROM OPERATIONS increased $5,623,000, or 34%, principally
because of the increase in net sales. It was 33% of sales in the first three
quarters of 2002, as compared with 32% of sales in the first three quarters of
2001.
INVESTMENT INCOME decreased $547,000, or 37%, as compared with the
first three quarters of 2001, notwithstanding an approximate 40% increase in the
average investment portfolio in the first three quarters of 2002 compared with
the first three quarters of 2001. This was because of the effect of declines in
interest rates since the beginning of 2001.
INCOME TAXES were accrued at an effective tax rate of 37% in the first
three quarters of both 2002 and 2001.
NET INCOME increased $3,181,000, or 30%, to $13,797,000 as compared
with $10,616,000 for the first nine months of 2001. NET INCOME PER SHARE -
DILUTED increased 22% to $0.90 per share in the first nine months of 2002 as
compared with $0.74 for the first nine months of 2001. This was a lower
percentage than the increase in net income because of increases in both the
weighted average number of shares outstanding and the dilutive effect of stock
options.
LIQUIDITY AND CAPITAL RESOURCES
- -------------------------------
During the nine months ended September 30, 2002, our cash and cash
equivalents and investment securities position increased $17,192,000 to
$90,219,000 from $73,027,000 at December 31, 2001. Cash provided by operating
activities of $9,834,000 (excluding tax benefits from exercise of stock options)
and the exercise of stock options of $15,804,000 (including tax benefits) was
partially offset by the cost of additions of $8,446,000 to property and
equipment. Cash provided by stock options, including tax benefits, was
$15,804,000 in the first three quarters of 2002 as compared with $4,474,000 in
the first three quarters of 2001; options were exercised on 812,544 shares in
the first three quarters of 2002 as compared with 353,764 shares in the first
three quarters of 2001.
We expect that sales of our products will continue to grow in 2002. If
sales continue to increase, accounts receivable and inventories are expected to
increase as well. As a result of these and other factors, including increased
capital expenditures, our working capital requirements may increase in the
foreseeable future. At September 30, 2002, inventories were $5,326,000 as
compared with $1,594,000 at December 31, 2001, or an increase of $3,732. Raw
material increased $1,396,000 because we increased the amounts of components in
16
stock to avoid lack of components needed to meet production schedules. A number
of suppliers showed an inability to reliably meet the demands of our increased
volume. Finished good increased $2,104,000 from $125,000 at December 31, 2001 in
order to meet anticipated customer requirements in the fourth quarter of 2002
and because of a scheduled production shutdown in the latter half of December
2002 to perform extensive preventive maintenance.
We currently expect that capital expenditures for property and
equipment will be between approximately $13 million and $14 million in 2002.
We are making additional investments in molding machines, molds and automated
assembly machines as well as recurring facilities improvements and acquisition
of computer equipment and software. We are also acquiring sterilization
equipment to support our assembly facility in Mexico, and expanding that
facility. We are also replacing our current enterprise software with Oracle
Corporation's R11i business suite at a cost of over $1 million; we expect most
of the new software will be installed in the fourth quarter of 2002, and that it
will substantially enhance our business and information processes.
We are currently evaluating the design and capacity of our
manufacturing facilities. We estimate that our current facilities and additions
in process in 2002 will be adequate through 2003, but that production after 2003
will require additional clean room facilities for molding and automated
assembly. We expect to decide later in the year how to meet the need for
additional facilities and the location of additional clean room facilities for
molding and automated assembly.
In a series of transactions from October 31 to November 13, 2002, we
acquired Bio-Plexus, Inc. for approximately $10 million cash and assumption of
$1.2 million of debt. We currently estimate transaction costs and integration
costs will aggregate approximately $1 million. Bio-Plexus is located in Vernon,
Connecticut. Its principal products are blood collection needles under the
PUNCTURE-GUARD(R) name, which are designed to eliminate exposure to sharp,
contaminated needles. Bio-Plexus's sales for its year ended December 31, 2001
were $6.4 million. Its operating losses in recent months approximate $250,000
per month. Bio-Plexus will be included in our consolidated financial statements
commencing November 1, 2002. We are in the process of implementing significant
expense reductions at Bio-Plexus that are part of our integration of
Bio-Plexus's operations with our operations.
We have not purchased treasury stock since October 1999, except for a
small amount in March 2000. We may purchase additional shares in the future.
However, future acquisitions, if any, will depend on market conditions and other
factors.
We have a large cash and liquid investment position generated from
profitable operations and stock sales, principally from the exercise of employee
stock options. We maintain this position to fund our growth, meet increasing
working capital requirements, fund capital expenditures, and potentially to take
advantage of acquisition opportunities that may arise. Our primary investment
goal is capital preservation, so, as further described below in "Quantitative
and Qualitative Disclosures about Market Risk," our liquid investments have very
little credit risk or market risk.
We believe that our existing working capital, supplemented by income
from operations, will be sufficient to fund capital expenditures and increased
working capital requirements for the foreseeable future.
17
FORWARD LOOKING STATEMENTS
- --------------------------
Various portions of this Report, including this Management's Discussion
and Analysis, describe trends in our business and finances that we perceive and
state some of our expectations and beliefs about our future. These statements
about the future are "forward looking statements," and we identify them by using
words such as "believes," "expects," "estimates," "plans," "will," "continue,"
"could," and by similar expressions and statements about aims, goals and plans.
The forward looking statements are based on the best information currently
available to us and assumptions that we believe are reasonable, but we do not
intend the statements to be representations as to future results. They include,
among other things, statements about:
o future operating results and various elements of operating results,
including sales and unit volumes of products, future increases in sales of
custom and generic I.V. systems, production costs, gross margins, SG&A, and
R&D expense and income taxes;
o factors affecting operating results, such as shipments to specific
customers, foreign sales, product mix, quarterly sales fluctuations,
selling prices, the market shift to needleless and swabbable products,
increases or declines in sales of certain products, impact of safety
legislation, achievement of business expansion goals, development of
innovative systems capabilities, introduction and sales of new products,
direct sales of commodity-type I.V. sets, manufacturing efficiencies, labor
costs, unit production costs, acquisition and use of production equipment
and expansion of facilities and assembly capacity, expansion of markets,
and establishment of production facilities outside North America;
o new or extended contracts with manufacturers and buying organizations, and
dependence on a small number of customers;
o regulatory approval and outcome of litigation;
o competitive and market factors, including continuing development of
competing products by other manufacturers, consolidation of the healthcare
provider market and downward pressure on selling prices; and
o working capital requirements, changes in accounts receivable and
inventories, capital expenditures and common stock repurchases.
The kinds of statements described above and similar forward looking
statements about our future performance are subject to a number of risks and
uncertainties which one should consider in evaluating the statements. First, one
should consider the factors and risks described in the statements themselves.
Those factors are uncertain, and if one or more of them turn out differently
than we currently expect, our operating results may differ materially from our
current expectations.
Second, one should read the forward looking statements in conjunction
with the Risk Factors in our Current Report on Form 8-K to the Securities and
Exchange Commission dated February 15, 2002 which is incorporated by reference.
Third, our actual future operating results are subject to other
important factors that we cannot predict or control, including among others the
following:
o general economic and business conditions;
o the effect of price and safety considerations on the healthcare industry;
o competitive factors, such as product innovation, new technologies,
marketing and distribution strength and price erosion;
o unanticipated market shifts and trends;
o the impact of legislation affecting government reimbursement of healthcare
costs;
o changes by our major customers and independent distributors in their
strategies that might affect their efforts to market our products or
products incorporating our products;
o unanticipated production problems; and
o the availability of patent protection and the cost of enforcing and of
defending patent claims.
18
We disclaim any obligation to update the statements or to announce
publicly the result of any revision to any of the statements contained herein to
reflect future events or developments.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
- -------------------------------------------------------------------
We have a portfolio of corporate preferred stocks and
federal-tax-exempt state and municipal government debt securities. The
securities are all "investment grade" and we believe that we have virtually no
exposure to credit risk. Dividend and interest rates reset at auction for most
of the securities from between seven and forty-nine day intervals, with some
longer but none beyond twelve months, so we have very little market risk, that
is, risk that the fair value of the security will change because of changes in
market interest rates.
Our future earnings are subject to potential increase or decrease
because of changes in short-term interest rates. Generally, each one-percentage
point change in the discount rate will cause our overall yield to change by
two-thirds to three-quarters of a percentage point, depending upon the relative
mix of federal-tax-exempt securities and corporate preferred stocks in the
portfolio and market conditions specific to the securities in which we invest.
We do not have any significant foreign currency risk. Sales to foreign
distributors are all denominated in U.S. dollars. Cash and receivables in
entities outside the United States, principally in Mexico, which are denominated
in foreign currency are insignificant and are generally offset by accounts
payable in the same foreign currency.
ITEM 4. CONTROLS AND PROCEDURES
- --------------------------------
Our principal executive officer and principal financial officer have
concluded, based on their evaluation of our disclosure controls and procedures
(as defined in Regulations 13a-14(c) and 15a-14(c) under the Securities and
Exchange Act of 1934) within 90 days of filing this Report, that our disclosure
controls and procedures are effective to ensure that the information we are
required to disclose in the reports that we file or submit under the Exchange
Act is accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate to allow
timely decisions regarding required disclosure and that such information is
recorded, processed, summarized and reported within the time periods specified
in the rules and forms of the Securities Exchange Commission. There were no
significant changes in our internal controls or in other factors that could
significantly affect our internal controls subsequent to the date of the
principal executive officer's and principal financial officer's evaluation,
including any corrective actions with regard to significant deficiencies and
material weaknesses.
PART II
OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
- --------------------------
In an action filed August 21, 2001 entitled ICU Medical, Inc. v. B.
Braun Medical, Inc. pending in the United States District Court for the Northern
District of California, we allege that B.Braun Medical, Inc. infringes ICU's
patent by the manufacture and sale of its UltraSite medical connector. We seek
monetary damages and injunctive relief and intend to vigorously pursue this
matter. The outcome of this matter cannot be determined at this time.
19
We are from time to time involved in various other legal proceedings,
either as a defendant or plaintiff, most of which are routine litigation in the
normal course of business. We believe that the resolution of the legal
proceedings in which we are involved will not have a material adverse effect on
our financial position or results of operations.
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
- --------------------------------------------------
Inapplicable
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
- ----------------------------------------
Inapplicable
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
- ------------------------------------------------------------
Inapplicable
ITEM 5. OTHER INFORMATION
- --------------------------
None
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
- ----------------------------------------
(a) Exhibits:
Exhibit 99.1 Certifications of Chief Executive Officer and Chief
Financial Officer
(b) Reports on Form 8-K: None
20
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ICU Medical, Inc.
(Registrant)
/s/ Francis J. O'Brien Date: November 14, 2002
------------------
Francis J. O'Brien
Chief Financial Officer
(Principal Financial Officer and)
Chief Accounting Officer)
21
Annex A
I, the Chief Executive Officer, certify that:
1. I have reviewed this quarterly report on Form 10-Q of ICU Medical,
Inc.:
2. Based on my knowledge, this quarterly report does not contain any
untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this
quarterly report;
3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure
that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this quarterly report
is being prepared;
b) evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to the filing
date of this quarterly report (the "Evaluation Date"); and
c) presented in this quarterly report our conclusions about
the effectiveness of the disclosure controls and procedures based on
our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed,
based on our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's auditors and the audit committee of registrant's board
of directors:
a) all significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's ability
to record, process, summarize and report financial data and have
identified for the registrant's auditors any material weaknesses in
internal controls; and
b) any fraud, whether or not material, that involved
management or other employees who have a significant role in the
registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in
this quarterly report whether or not there were any significant changes in
internal controls or in other factors that could significantly affect internal
controls subsequent to the date of our most recent evaluation, including any
corrective actions with regard to significant deficiencies and material
weaknesses.
Date: November 14, 2002
/s/ George A. Lopez, M.D.
-------------------------
Chief Executive Officer
22
Annex A
I, the Chief Financial Officer, certify that:
1. I have reviewed this quarterly report on Form 10-Q of ICU Medical,
Inc.:
2. Based on my knowledge, this quarterly report does not contain any
untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this
quarterly report;
3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure
that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this quarterly report
is being prepared;
b) evaluated the effectiveness of the registrant's disclosure
controls and procedures as of a date within 90 days prior to the filing
date of this quarterly report (the "Evaluation Date"); and
c) presented in this quarterly report our conclusions about
the effectiveness of the disclosure controls and procedures based on
our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed,
based on our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's auditors and the audit committee of registrant's board
of directors:
a) all significant deficiencies in the design or operation of
internal controls which could adversely affect the registrant's ability
to record, process, summarize and report financial data and have
identified for the registrant's auditors any material weaknesses in
internal controls; and
b) any fraud, whether or not material, that involved
management or other employees who have a significant role in the
registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in
this quarterly report whether or not there were any significant changes in
internal controls or in other factors that could significantly affect internal
controls subsequent to the date of our most recent evaluation, including any
corrective actions with regard to significant deficiencies and material
weaknesses.
Date: November 14, 2002
/s/ Francis J. O'Brien
----------------------
Chief Financial Officer
23